PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy

Journal of Experimental Medicine

Volumn 180, Issue 1, 1994, Pages 283-296

  Vallat, Val Pierre ^a   Gilleaudeau, Patricia ^a   Battat, Lisa ^a   Wolfe, Jonathan ^a   Nabeya, Reiko ^a   Heftier, Noah ^a   Hodak, Emmilia ^a   Gottlieb, Alice B ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN RECEPTOR; PSORALEN; SOMATOMEDIN C RECEPTOR;

ADULT; ARTICLE; BALNEOTHERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; DERMIS; EPIDERMIS; HUMAN; HUMAN TISSUE; KERATINOCYTE; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; PSORIASIS; REMISSION; T LYMPHOCYTE ACTIVATION; ULTRAVIOLET A RADIATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD1; CELLS, CULTURED; CYCLOSPORINE; EPIDERMIS; HLA-DR ANTIGENS; HUMAN; KI-67 ANTIGEN; LYMPHOCYTE ACTIVATION; MIDDLE AGE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PSORIASIS; PUVA THERAPY; SKIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028223483     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.180.1.283     Document Type: Article

References (52)

1. Weinstein, G.D., and P. Frost. 1968. Abnormal cell proliferation in psoriasis. J. Invest. Dermatol. 50:254.
2. Mansbridge, J.N., and A.M. Knapp. 1987. Changes in ker-atinocyte maturation during wound healing. J. Invest. Dermatol. 89:253.
3. Bemerd, F., T. Magnaldo, and M. Darmon. 1992. Delayed onset of epidermal differentiation in psoriasis. J. Invest. Dermatol. 98:902.
4. Gottlieb, A.B., B. Lifshitz, S.M. Fu, L. Staiano-Coico, C.Y. Wang, and D.M. Carter. 1986. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J. Exp. Med. 164:1013.
5. Terui, T., S. Aiba, T. Tanaka, and H. Tagami. 1987. FILA-DR antigen expression on keratinocytes in highly inflamed parts of psoriatic lesions. Br. J. Dermatol. 116:87.
6. Baker, B.S., A.F. Swain, L. Fry, and H. Valdimarsson. 1984. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br. J. Dermatol. 11:555.
7. Singer, K.H., D.T. Tuck, H.A. Sampson, and R.P. Hall. 1989. Epidermal keratinocytes express the adhesion molecule intercellular adhesion molecule-1 in inflammatory dermatoses. J. Invest. Dermatol. 92:746.
8. Lisby, S., E. Ralfkiaer, R. Rothlein, and G.L. Vejlsgaard. 1989. Intercellular adhesion molecule-I (ICAM-I) expression correlated to inflammation. Br. J. Dermatol. 120:479.
9. Gottlieb, A.B., A.D. Luster, D.N. Posnett, and D.M. Carter. 1988. Detection of a 'y-interferon-induced protein (IP-10) in psoriatic plaques. J. Exp Med. 168:941.
10. Krueger, J.G., J.F. Krane, D.M. Carter, and A.B. Gottlieb. 1990. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J. Invest. Dermatol. 94:135S.
11. Nickoloff, B.J. 1991. The cytokine network in psoriasis. Arch. Dermatol. 127:871.
12. Cooper, K.D. 1990. Psoriasis: leukocytes and cytokines. Dermatology Clinics. 8:737.
13. 125I-epidermal growth factor binding and receptor distribution in psoriasis. J. Invest. Dermatol. 86:260.
14. Krane, J.F., A.B. Gottlieb, D.M. Carter, andJ.G. Krueger. 1992. The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J. Exp Med. 175:1081.
15. Kupper, T.S. 1990. Immune and inflammatory processes in cutaneous tissues. Mechanisms and speculations. J. Clin. Invest. 86:1783.
16. Krueger, J.G., and A.B. Gottlieb. 1994. Growth Factors, Cytokines, and Eicosanoids. In Psoriasis. L. Dubertret, editor. ISED Publishing Co., Bresca, Italy. 18-28.
17. Weinstein, G.D., and J.G. Krueger. 1994. Overview of Psoriasis. In Therapy of Moderate to Severe Psoriasis. G.D. Weinstein, and A.B. Gottlieb, editors. National Psoriasis Foundation, Portland, Oregon. 1-22.
18. Vassar, R., and E. Fuchs. 1991. Transgenic mice provide new insights into the role of TGF-oi during epidermal development and differentiation. Genes & Dev. 5:714.
19. Turksen, K., T. Kupper, L. Degenstein, I. Williams, and E. Fuchs. 1992. Interleukin 6: insights into its function in skin by over expression in transgenic mice. Proc Natl. Acad. Sci. USA. 89:5068.
20. Hammer, R.E., S.D. Maika, J.A. Richardson, J.P. Tang, and J.D. Taurog. 1990. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human j32m: an animal model of HLA-B27-associated human disorders. Cell. 63:1099.
21. Ellis, C.N., M.S. Fradin, J.M. Messana, M.D. Brown, M.T. Siegel, A.H. Hartley, L.L. Rocher, S. Wheeler, T.A. Hamilton, T.G. Parish, et al. 1991. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N. EnglJ. Med. 324:277.
22. Fry, L. 1989. The role of the T cell in psoriasis and the action of cyclosporin in this disease. Acta. Dermato-Venereol (Stockh). 146:133.
23. Bos, J.D., M.M. Meinardi, T. Vanjoost, F. Heule, andL. Fry. 1989. Use of cyclosporin in psoriasis. Lancet. 23:1500.
24. Lowe, N.J., D. Weingarten, T. Bourget, and L.S. Moy. 1986. PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen. J. Am. Acad. Dermatol. 14:754.
25. Collins, P., and S. Rogers. 1991. Bath-water delivery of 8-methoxypsoralen therapy for psoriasis. Clin. Exp Dermatol. 16:165.
26. Lindelof, B., B. Sigurgeirsson, E. Tegner, O. Larko, and B. Berne. 1992. Comparison of the carcinogenic potential of tri-oxsalen bath PUVA and oral methoxsalen PUVA. Arch. Dermatol. 128:1341.
27. Gottlieb, A.B., R.M. Grossman, L. Khandke, D.M. Carter, P.B. Sehgal, S.M. Fu, A. Granelli-Piperno, M. Rivas, L. Barazani, and J.G. Krueger. 1992. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J. Invest. Dermatol. 98:302.
28. Petzelbauer, P., G. Stingl, K. Wolff, and B. Volc-Platzer. 1991. Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J. Invest. Dermatol. 96:362.
29. Khandke, L., R. Ashinoff, J.F. Krane, L. Staiano-Coico, A. Granelli-Piperno, A.D. Luster, D.M. Carter, J.G. Krueger, and A.B. Gottlieb. 1991. Cyclosporine in psoriasis treatment: inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor-cr/epidermal growth factor receptor pathways. Arch. Dermatol. 127:1172.
30. Vallat, V.P., P. Gilleaudeau, L. Battat, J. Wolfe, N. Heftier, S. Gottlieb, E. Hodak, A.B. Gottlieb, and J.G. Krueger. 1994. PUVA bath therapy. In Therapy of Moderate to Severe Psoriasis. G.D. Weinstein, and A.B. Gottlieb, editors. National Psoriasis Foundation, Portland, Oregon. 39-55.
31. Grossman, R.M., J. Krueger, D. Yourish, A. Granelli-Piperno, D. P. Murphy, L.T. May, T.S. Kupper, P.B. Sehgal, and A.B. Gottlieb. 1989. Interleukin-6 (IL-6) is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA. 86:6367.
32. Weiss, R.A., G.Y.A. Guillet, I.M. Freedberg, E.R. Farmer, E. A. Small, M.M. Weiss, and TT. Sun. 1983. The use of monoclonal antibody to keratin in human epidermal disease: alterations in immunohistochemical staining pattern. J Invest. Dermatol. 81:224.
33. Gottlieb, A.B., C.K. Chang, D.N. Posnett, B. Fanelli, and J.P. Tam. 1988. Detection of transforming growth factor a in normal, malignant, and hyperproliferative human keratinocytes. J. Exp Med. 167:670.
34. Smoller, B.A., N.S. McNutt, D.M. Carter, A.B. Gottlieb, A. Hsu, and J. Krueger. 1990. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated im-munophenotype. Arch. Dermatol. 126:78.
35. Krane, J.F., D.P. Murphy, D.M. Carter, and J.G. Krueger. 1991. Synergistic effects of epidermal growth factor (EGF) and insulin-like growth factor (EGF) and insulin-like growth factor 1/somatomedin C (IGF-1) on kératinocyte proliferation may be mediated by IGF-1 transmodulation of the EGF receptor. J. Invest. Dermatol. 96:419.
36. Koulu, L., K.O. Söderström, and C.T. Jansen. 1984. Relation of antipsoriatic and Langerhans cell depleting effects of systemic psoralen photochemotherapy: a clinical enzyme histo-chemical, and electron microscopic study. J. Invest. Dermatol. 84:591.
37. Bos, J.D., and S.R. Krieg. 1985. Psoriasis infiltrating cell immunophénotype: changes induced by PUVÀ or corticosteroid treatment in T-cell subsets, Langerhans’ cell and interdigitating cells. Acta. Dermato-Vemereol. (Stockh). 65:390.
38. Czernielewski, J., L. Juhlin, S. Shroot, and P. Brun. 1985. Langerhans’ cells in patients with psoriasis: effect of treatment with PUVA, PUVA bath, etretinate and anthralin. Acta. Dermato-Venereol. 65:97.
39. Gommans, J.M., S.J.T.M. Van Hezik, and B.E.W.L. Van Huystee. 1987. Flow cytometric quantification of T6-positive cells in psoriatic epidermis after PUVA and methotrexate therapy. Br. J. Dermatol. 116:661.
40. Koulu, L.M., and C.T. Jansen. 1988. Antipsoriatic, erythemato-genic, and Langerhans cell marker depleting effect of bath-psoralens plus ultraviolet A treatment. J. Am. Acad. Dermatol. 18:1053.
41. + Langerhans cells exhibit normal alloantigen-presenting function. Br. J. Dermatol. 120:329.
42. Bruno, S., and Z. Darzynkiewicz. 1992. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell. Proliferation. 25:31.
43. Elder, J.T., G.J. Fisher, P.B. Lindquist, G.L. Bennett, M.R. Pittelkow, R.J. Coffey, L. Ellingsworth, R. Derynck, and J.J. Voorhees. 1989. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science (Wash. DC). 243:811.
44. Huuskonen, H., L. Koulu, and G. Wilen. 1984. Quantitative determination of methoxsalen in human serum, suction blister fluid and epidermis by gas chromatography mass spectrometry. Photodermatology. 1:137.
45. Kruger, J.P., E. Christophers, and M. Schlaak. 1978. Doseeffects of 8-methoxypsoralen and UVA in cultured human lymphocytes. Br. J. Dermatol. 98:141.
46. Bickers, D.R. 1989. Photobiology 1937-1987. J. Invest. Dermatol. 92:25S.
47. Gupta, A.K., and T.F. Anderson. 1987. Psoralen photochemotherapy. J. Am. Acad. Dermatol. 17:703.
48. Burger, P.M., J.G. Tijssen, and P. Suurmond. 1981. Photochemotherapy of psoriasis. Clinical study of clearing and longterm maintenance treatment. Dermatologica (Basel). 163:213.
49. Nabeya, R., L. Staiano-Coico, A. Gottlieb, and J. Krueger. 1994. PUVA treatment induces human keratinocyte differentiation in vitro and in psoriatic epidermis. J. Invest. Dermaol. 102:531. (Abstr.)
50. Bata-Csorgo, Z., C. Hammerberg, J.J. Voorhees, and K.D. Cooper. 1993. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J. Exp Med. 178:1271.
51. Hancock, G.E., G. Kaplan, and Z.A. Cohn. 1988. Keratinocyte growth regulation by the products of immune cells. J. Exp Med. 168:1395.
52. Wong, R.L., C.M. Winslow, and K.D. Cooper. 1994. Immunol. Today. 14:69.